A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(55 sites)

United States

Local Institution - 0077, Anaheim, California

Local Institution - 0058, Chino, California

Local Institution - 0083, Redlands, California

Local Institution - 0089, San Francisco, California

Local Institution - 0032, Orlando, Florida

Atlanta Center for Medical Research, Atlanta, Georgia

Local Institution - 0103, Lawrenceville, Georgia

Local Institution - 0039, Stone Mountain, Georgia

Local Institution - 0044, Chicago, Illinois

Local Institution - 0105, Evanston, Illinois

Local Institution - 0076, Boston, Massachusetts

Local Institution - 0104, Brookline, Massachusetts

Local Institution - 0059, Worcester, Massachusetts

Local Institution - 0061, Great Neck, New York

Local Institution - 0051, Cincinnati, Ohio

Local Institution - 0097, Philadelphia, Pennsylvania

Local Institution - 0046, Garland, Texas

Local Institution - 0090, McAllen, Texas

Local Institution - 0066, Spring, Texas

Local Institution - 0050, Richmond, Virginia

Canada

Local Institution - 0111, Edmonton, Alberta

Local Institution - 0110, Kingston, Ontario

Local Institution - 0113, Toronto, Ontario

Local Institution - 0112, Montreal, Quebec

France

Local Institution - 0118, Bordeaux

Local Institution - 0120, Bron

Local Institution - 0119, Paris

Germany

Local Institution - 0121, Gdansk

Hungary

Local Institution - 0129, Budapest

Local Institution - 0130, Gyula

Local Institution - 0131, Szeged

Japan

Local Institution - 0075, Chikugo, Fukuoka

Local Institution - 0073, Sapporo, Hokkaido

Local Institution - 0025, Zentsujichó, Kagawa-ken

Local Institution - 0062, Miyakonojō, Miyazaki

Local Institution - 0086, Bunkyo-ku, Tokyo

Local Institution - 0056, Ōta-ku, Tokyo

Local Institution - 0063, Yokohama, Kanagawa

Poland

Local Institution - 0128, Poznan, Greater Poland Voivodeship

Local Institution - 0125, Wroclaw, Lower Silesian Voivodeship

Local Institution - 0122, Kraśnik, Lublin Voivodeship

Local Institution - 0127, Warsaw, Masovian Voivodeship

Local Institution - 0126, Gdansk, Pomeranian Voivodeship

Local Institution - 0123, Szczecin, West Pomeranian Voivodeship

Local Institution - 0124, Katowice

Romania

Local Institution - 0029, Bucharest, Bucharest

Local Institution - 0031, Cluj-Napoca, Cluj

Local Institution - 0040, Bucharest

Local Institution - 0042, Bucharest

Local Institution - 0008, Iași

Local Institution - 0038, Timișoara

Spain

Local Institution - 0101, Barcelona

Local Institution - 0099, Barcelona

Local Institution - 0098, Madrid

Local Institution - 0100, Madrid

View full record on ClinicalTrials.gov

Trial locations(55 sites)

Interested in joining?